Cytosorbents (NASDAQ:CTSO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update [Yahoo! Finance]
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
Cytosorbents (NASDAQ:CTSO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path Transcript [Seeking Alpha]